<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00936897</url>
  </required_header>
  <id_info>
    <org_study_id>20080562</org_study_id>
    <nct_id>NCT00936897</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates</brief_title>
  <official_title>A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, open-label, parallel group, study being conducted in the
      United States and in Europe in postmenopausal women. Approximately 800 subjects will be
      randomized across about 65 sites in a 1:1 ratio to either denosumab 60mg SC Q6M, or
      ibandronate 150mg PO QM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline to month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1</measure>
    <time_frame>Baseline to month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>Baseline to month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">833</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Ibandronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibandronate 150mg PO QM (tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>denosumab 60mg Subcutaneous Q6M (pre-filled syringe)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>Ibandronate 150mg PO QM (tablet)</description>
    <arm_group_label>Ibandronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>denosumab 60mg SC Q6M (pre-filled syringe)</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, postmenopausal women (based on medical history) 55 years or older at
             screening

          -  Postmenopause will be defined as no vaginal bleeding or spotting for at least 12
             months

          -  If the subject is 55 - 59 years old and there is uncertainty regarding menopausal
             status, confirmation of serum FSH (&gt;= 50 mIU/mL) and serum estradiol (&lt;= 20 pg/mL)
             must be obtained

          -  If the subject is 60 years or older, evaluation of FSH and estradiol levels is not
             needed to confirm menopausal status

          -  Have received their first prescription of daily or weekly bisphosphonate therapy at
             least 1 month prior to screening

          -  May have received

          -  raloxifene, calcitonin, prior to initiation of daily orweekly bisphosphonate therapy.

          -  up to 3 doses of monthly bisphosphonate prior to initiation of daily or weekly
             bisphosphonate therapy

          -  calcium, and vitamin D

          -  Hormone replacement therapy (e.g. estrogen use for mitigation of menopausal symptoms)

          -  Subject has:

          -  Stopped daily or weekly bisphosphonate therapy (is denoted as non-persistent) at least
             one month before the screening visit, or

          -  Demonstrated low adherence to therapy assessed by a score of less than 6 on the
             OS-MMAS

          -  Screening BMD (g/cm2) values, at the lumbar spine OR total hip, that occur within the
             following ranges, based on the particular scanner that is used:

        GE Lunar Lumbar spine 0.700 &lt; or = BMD &lt; and = 0.940 Total hip 0.504 &lt; or = BMD &lt; or =
        0.756

        Hologic Lumbar spine 0.607 &lt; or = BMD &lt; or = 0.827 Total hip 0.454 &lt; or = BMD &lt; or = 0.698
        Both the initial and the repeat DXA scan of the lumbar spine OR the total hip must meet the
        above eligibility criteria.

          -  At least 2 lumbar vertebrae must be evaluable by DXA.

          -  At least one hip must be evaluable by DXA (eg, no history of either bilateral hip
             replacement or pins in both hips)

          -  Provide signed informed consent before any study-specific procedures are conducted

        Exclusion Criteria:

          -  Any disorder that compromises the ability of the subject to give written informed
             consent and/or to comply with study procedures

          -  Current or prior use of medications prescribed for osteoporosis treatment other than
             oral daily or weekly bisphosphonate

          -  Contraindicated to receive oral ibandronate 150mg PO QM, including

          -  Hypersensitivity to ibandronate 150mg PO QM or other constituents of ibandronate 150mg
             PO QM tablets

          -  Abnormalities of the esophagus, which delay esophageal emptying such as stricture or
             achalasia

          -  Inability to stand or sit upright for at least 60 minutes

          -  Administration of any of the following treatments within 3 months of screening

          -  Tibolone

          -  Anabolic steroids or testosterone

          -  Glucocorticosteroids (&gt;= 5 mg prednisone equivalent per day for more than 10 days or a
             total cumulative dose of &gt;= 50 mg)

          -  Vitamin D deficiency [25(OH) vitamin D level &lt; 20 ng/mL (&lt;49.9 nmol/L)] - Repletion
             will be allowed and subjects may be re-screened

          -  Evidence of any of the following per subject report, chart review or central
             laboratory result:

          -  Significantly impaired renal function as determined by estimated Glomerular Filtration
             Rate less that 30mL/min/1.73 m2 determined by the central laboratory

          -  Current hypo- or hypercalcemia based on the central laboratory reference ranges

          -  Active gastric or duodenal ulcer; or any history of significant gastrointestinal bleed
             requiring hospitalization or transfusion

          -  Known to have tested positive for human immunodeficiency virus, hepatitis C virus, or
             hepatitis B surface antigen

          -  Malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma,
             cervical or breast ductal carcinoma in situ) within the last 5 years

          -  Any metabolic bone disease or secondary cause of bone loss that is not controlled and
             may interfere with the interpretation of the findings

          -  Previous participation in clinical trials with denosumab 60mg SC Q6M (regardless of
             treatment)

          -  Received any solid organ or bone marrow transplant

          -  Any laboratory abnormality which, in the opinion of the investigator, will prevent the
             subject from completing the study or interfere with the interpretation of the study
             results

          -  Known sensitivity to mammalian cell derived drug products

          -  Known intolerance to calcium supplements

          -  Currently enrolled in or has not yet completed at least 1 month since ending other
             investigational device or drug trial(s)

          -  Any physical or psychiatric disorder which, in the opinion of the investigator, will
             prevent the subject from completing the study or interfere with the interpretation of
             the study results

          -  Evidence of alcohol or substance-abuse within the last 12 months which the
             investigator believes would interfere with understanding or completing the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <results_first_submitted>October 31, 2012</results_first_submitted>
  <results_first_submitted_qc>October 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>February 5, 2013</last_update_submitted>
  <last_update_submitted_qc>February 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized from 29 July 2009 through 5 November 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab 60 mg SC Q6M</title>
          <description>Denosumab 60 mg subcutaneous once every 6 months</description>
        </group>
        <group group_id="P2">
          <title>Ibandronate 150 mg PO QM</title>
          <description>Ibandronate 150 mg oral monthly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="417">Randomized</participants>
                <participants group_id="P2" count="416">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="398"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility Determined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab 60 mg SC Q6M</title>
          <description>Denosumab 60 mg subcutaneous once every 6 months</description>
        </group>
        <group group_id="B2">
          <title>Ibandronate 150 mg PO QM</title>
          <description>Ibandronate 150 mg oral monthly</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="417"/>
            <count group_id="B2" value="416"/>
            <count group_id="B3" value="833"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="8.1"/>
                    <measurement group_id="B2" value="66.2" spread="7.8"/>
                    <measurement group_id="B3" value="66.7" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="417"/>
                    <measurement group_id="B2" value="416"/>
                    <measurement group_id="B3" value="833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>Baseline to month 12</time_frame>
        <population>All randomized subjects using regression imputation for missing post baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg SC Q6M</title>
            <description>Denosumab 60 mg subcutaneous once every 6 months</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg PO QM</title>
            <description>Ibandronate 150 mg oral monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <population>All randomized subjects using regression imputation for missing post baseline data.</population>
          <units>Percentage Change From Baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="2.0" upper_limit="2.5"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.6" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
            <estimate_desc>Denosumab - Ibandronate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1</title>
        <time_frame>Baseline to month 1</time_frame>
        <population>Randomized subjects who enrolled in the bone marker substudy</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg SC Q6M</title>
            <description>Denosumab 60 mg subcutaneous once every 6 months</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg PO QM</title>
            <description>Ibandronate 150 mg oral monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Type-1 C-Telopeptide Percent Change From Baseline at Month 1</title>
          <population>Randomized subjects who enrolled in the bone marker substudy</population>
          <units>Percentage Change From Baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.1" lower_limit="-88.0" upper_limit="-70.9"/>
                    <measurement group_id="O2" value="-35.0" lower_limit="-51.9" upper_limit="-15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>Baseline to Month 12</time_frame>
        <population>All randomized subjects using regression imputation for missing post baseline data</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg SC Q6M</title>
            <description>Denosumab 60 mg subcutaneous once every 6 months</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg PO QM</title>
            <description>Ibandronate 150 mg oral monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <population>All randomized subjects using regression imputation for missing post baseline data</population>
          <units>Percentage Change From Baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
            <estimate_desc>Denosumab - Ibandronate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <time_frame>Baseline to month 12</time_frame>
        <population>All randomized subjects using regression imputation for missing post baseline data</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab 60 mg SC Q6M</title>
            <description>Denosumab 60 mg subcutaneous once every 6 months</description>
          </group>
          <group group_id="O2">
            <title>Ibandronate 150 mg PO QM</title>
            <description>Ibandronate 150 mg oral monthly</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <population>All randomized subjects using regression imputation for missing post baseline data</population>
          <units>Percentage Change From Baseline</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="415"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="3.7" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.7" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Denosumab - Ibandronate</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events. Participant flow includes all subjects randomized to the study. Number of subjects at risk of an adverse events are based on safety population â€“ all randomized subjects who received at least one dose of treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibandronate 150 mg PO QM</title>
          <description>Ibandronate 150 mg oral monthly</description>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg SC Q6M</title>
          <description>Denosumab 60 mg subcutaneous once every 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Internal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Aortic injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Cardiac vein perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Heart injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic valve repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="410"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="411"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

